Cited by 327PARP inhibition in cancer therapyBRCA gene mutations in cancerCancer Genomics and Diagnostics

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

Open access

Watkins, Johnathan A, Irshad, Sheeba, Grigoriadis, Anita, Tutt, Andrew NJ·2014·Breast Cancer Research

Open this paper in CoChat — free account

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 genes, the products of which contribute to the conservative homologous recombination repair of DNA double-strand breaks. Nonetheless, several setbacks in clinical trial settings have highlighted some of the issues surrounding the investigation of PARP inhibitors, especially the identification of patients who stand to benefit from such drugs. One potential approach to finding this patient subpopulation is to examine the tumor DNA for evidence of a homologous recombination defect. However, although the genomes of many breast and ovarian cancers are replete with aberrations, the presence of numerous factors able to shape the genomic landscape means that only some of the observed DNA abnormalities are the outcome of a cancer cell's inability to faithfully repair DNA double-strand breaks. Consequently, recently developed methods for comprehensively capturing the diverse ways in which homologous recombination deficiencies may arise beyond BRCA1/2 mutation have used DNA microarray and sequencing data to account for potentially confounding features in the genome. Scores capturing telomeric allelic imbalance, loss of heterozygosity (LOH) and large scale transition score, as well as the total number of coding mutations are measures that summarize the total burden of certain forms of genomic abnormality. By contrast, other studies have comprehensively catalogued different types of mutational pattern and their relative contributions to a given tumor sample. Although at least one study to explore the use of the LOH scar in a prospective clinical trial of a PARP inhibitor in ovarian cancer is under way, limitations that result in a relatively low positive predictive value for these biomarkers remain. Tumors whose genome has undergone one or more events that restore high-fidelity homologous recombination are likely to be misclassified as double-strand break repair-deficient and thereby sensitive to PARP inhibitors and DNA damaging chemotherapies as a result of prior repair deficiency and its genomic scarring. Therefore, we propose that integration of a genomic scar-based biomarker with a marker of resistance in a high genomic scarring burden context may improve the performance of any companion diagnostic for PARP inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/bcr3670

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citation
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citation
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citation
Clonal evolution in cancer
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citation
Mutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909
Self-citation
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2013 · Cited by 1,743

Flagged first, then by citations

Show all 58 references

Research works printed but not linked: 1

de Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, Chadha M, Sachdev JC, Matei D, Jameson GS, Ong M, Basu B, Wainberg ZA, Byers LA, Chugh R, Dorr A, Kaye SB, Ramanthan RK: First-in human trial of novel oral PARP inhibitor BMN673 in patients with solid tumors. J Clin Oncol. 2013, 31: abstract 2580

Sorted by citations

Items 201–300 of 327

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1043 · Cited by 8
Stratification of Homologous Recombination Deficiency-Negative High-Grade Ovarian Cancer by the Type of Peritoneal Spread into Two Groups with Distinct Survival Outcomes
Schnaiter, S., Schamschula, E., Laschtowiczka, J., Fiegl, H., Zschocke, J., Zeimet, A. G., Wimmer, K., & Reimer, D. (2024) · Cancers · doi:10.3390/cancers16112129 · Cited by 8
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial
Villacampa, G. J., Llop‐Guevara, A., Filmann, N., Herencia-Ropero, A., Fasching, P. A., Karn, T., Marmé, F., Klare, P., Müller, V., Stefek, A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3148 · Cited by 8
Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 mutations: A case report
Zhong, R., Li, H., Liu, Y., Zhang, S., Liu, J., Huang, Z., & Cheng, Y. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13286 · Cited by 8
Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells
Gu, W., Lin, J., & Hong, X. Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20412 · Cited by 8
Pathogenese und genetischer Hintergrund des Osteosarkoms
Baumhoer, D. (2017) · Der Pathologe · doi:10.1007/s00292-017-0365-y · Cited by 8
Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group
Geiersbach, K. B., Chen, H., Emmadi, R., Haskell, G., Lu, X., Liu, Y. J., & Swisshelm, K. L. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.02.002 · Cited by 8
Evaluative Methodology for HRD Testing: Development of Standard Tools for Consistency Assessment
Jia, Z., Liu, Y., Qu, S., Li, W., Gao, L., Dong, L., Xing, Y., Cheng, Y., Fang, H., Yi, Y., et al. (2025) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzaf017 · Cited by 7
expHRD: an individualized, transcriptome-based prediction model for homologous recombination deficiency assessment in cancer
Lee, J.-J., Kang, H. J., Lim, S. O., Lim, S. O., Kim, S. S., Kim, G., Kim, J., Lee, J., & Kim, J. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05854-y · Cited by 7
HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data
Wang, X., Xu, Y., Zhang, Y., Wang, S., Zhang, X., Yi, X., Zhang, S., & Wang, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.990244 · Cited by 7
Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers
Reilly, N. M., Yard, B. D., & Pittman, D. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9500-4_1 · Cited by 9
Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
Franchet, C., Hoffmann, J., & Dalenc, F. (2021) · Cancers · doi:10.3390/cancers13164132 · Cited by 9
PARP inhibitors in gastric cancer: unlocking precision oncology
Tai, D., Goes, V., Kumar, S., Shah, P. D., Al-Manaseer, F., Park, D., Crook, C. J., Guzman, S., Zhu, X., Li, D., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf283 · Cited by 7
Long read sequencing reveals novel genomic and epigenomic alterations in repetitive regions of high grade serous ovarian cancer
Takamatsu, S., Li, J., Welte, T., Khlebus, E., Vuttaradhi, V. K., Brodsky, A. L., Lawson, B. C., & Hillman, R. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-21907-5 · Cited by 8
Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer
Zhang, L., Guan, S., Meng, F., Teng, L., & Zhong, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035808 · Cited by 6
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
Fernández‐Serra, A., López-Reig, R., Márquez, R., Gallego, A., de Sande, L. M., Yubero, A., Pérez, C. I. D., Vaswani, A. R., Barretina-Ginesta, M.-P., Mendizábal, E., et al. (2023) · Cancers · doi:10.3390/cancers15113030 · Cited by 6
Predictive and prognostic significance of BRCAness in HER2-negative breast cancer
Sueta, A., Yamamoto‐Ibusuki, M., Tomiguchi, M., Fujiki, Y., Goto‐Yamaguchi, L., Iwase, H., & Yamamoto, Y. (2022) · Breast Cancer · doi:10.1007/s12282-021-01319-9 · Cited by 6
DNA Damage Response and Cancer Metastasis: Clinical Implications and Therapeutic Opportunities
Yin, M., Hong, F., & Wang, Q.-E. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications.metastasis.dna-damage-response · Cited by 7
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Miller, R. E., & Ledermann, J. A. (2016) · PubMed · Cited by 6
PARP inhibitors and stratified treatment of prostate cancer
Lavery, A., Gilson, C., & Chowdhury, S. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1243474 · Cited by 6
Homologous recombination deficiency in epithelial ovarian cancer
Bartl, T., Paspalj, V., & Grimm, C. (2020) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-020-00606-z · Cited by 5
Methylation‐ and homologous recombination deficiency‐related mutant genes predict the prognosis of lung adenocarcinoma
Nie, G., Liu, J., Zou, A., Zhan, S., Liang, J., Sui, Y., Chen, Y., & Yao, W. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24277 · Cited by 4
Construction and validation of a histone acetylation-related lncRNA prognosis signature for ovarian cancer
Hu, X., Zhang, X.-C., Li, S.-T., & Hua, T. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.934246 · Cited by 5
Prediction of homologous recombination deficiency from cancer gene expression data
Kang, J. K., Lee, J., Lee, A., & Lee, Y. S. (2022) · Journal of International Medical Research · doi:10.1177/03000605221133655 · Cited by 5
A survey of cancer genome signatures identifies genes connected to distinct chromosomal instability phenotypes
Shafat, M. S., Rufaie, E. S., & Watkins, J. A. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-021-00217-9 · Cited by 5
Self-citation
Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation
Xue, S., Zhang, Y., Liu, F., Huang, W., Xu, R., & Wang, J. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1984453 · Cited by 5
CCR 20th Anniversary Commentary: Divide and Conquer—Breast Cancer Subtypes and Response to Therapy
Pusztai, L., Rouzier, R., & Symmans, W. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3121 · Cited by 5
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.01 · Cited by 5
Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity
Motonari, T., Yoshino, Y., Haruta, M., Endo, S., Sasaki, S., Miyashita, M., Tada, H., Watanabe, G., Kaneko, T., Ishida, T., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57367-6 · Cited by 4
Automated Scoring to Assess RAD51-Mediated Homologous Recombination in Ovarian Patient-Derived Tumor Organoids
Thorel, L., Elie, N., Morice, P., Weiswald, L., Florent, R., Perréard, M., Giffard, F., Ricou, A., Leman, R., Babin, G., et al. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104097 · Cited by 4
Detection of Genomic Copy Number Variations in Ovarian Cancer in the Peripheral Blood System
Wahl, L., Hliabtsova, U., Qian, X., Klopf, A., Hedemann, N., Flörkemeier, I., Rogmans, C., Kalab, M., Dempfle, A., Maass, N., et al. (2025) · Cancers · doi:10.3390/cancers17050780 · Cited by 4
Data-driven Sublanguage Analysis for Cancer Genomics Knowledge Modeling: Applications in Mining Oncological Genetics Information from Patients' Genetic Reports.
Zhao, Y., Yu, H., Fu, S., Shen, F., Davila, J. I., Liu, H., & Wang, C. (2020) · PubMed Central · Cited by 4
A narrative review of biomarkers in advanced triple negative breast cancer
Chehade, R., Awan, A. A., & Fernandes, R. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-20-76 · Cited by 4
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion
Vergote, I. B., Denys, H. G., Altıntaş, S., Kerger, J. N., Baurain, J. F., Bours, V., Henry, S., de Vijver, K. K. V., Lambrechts, D., & Gennigens, C. (2022) · Facts Views and Vision in ObGyn · doi:10.52054/fvvo.14.2.024 · Cited by 4
Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia
Čerina, D., Matković, V., Katić, K., Belac-Lovasić, I., Šeparović, R., Canjko, I., Bajić, Ž., & Vrdoljak, E. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071176 · Cited by 4
Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation
Sahajpal, N., Mondal, A. K., Vashisht, A., Singh, H., Pang, A. W. C., Saul, D., Omar, N., Hilton, B., DuPont, B. R., Kota, V. K., et al. (2023) · Genes · doi:10.3390/genes14091683 · Cited by 4
Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
(2023) · PubMed Central · Cited by 4
Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda
Jarroudi, O. A., Abda, N., Brahmi, S. A., & Afqir, S. (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.1.195 · Cited by 4
Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer
Tsilingiri, K., Chalari, A., Christopoulou, G., Voutsina, A., Constantoulakis, P., Potaris, Κ., Vamvakaris, I. N., Hatzidaki, D., Zachou, G., Vatsellas, G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00777-6 · Cited by 3
PARP1 in melanoma: Mechanistic insights and implications for basic and clinical research
Marranci, A., Maresca, L., Lodovichi, S., di Rorà, A. G. L., Stecca, B. A., & Poliseno, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217599 · Cited by 3
DNA double-strand repair by nonhomologous end joining and its clinical relevance
Setton, J. S., Bindra, R. S., & Powell, S. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00009-7 · Cited by 4
Targeting ATR for Cancer Therapy: ATR-Targeted Drug Candidates
Dillon, M. T., & Harrington, K. J. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-75836-7_5 · Cited by 3
Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions
Rabban, J. T., Chen, L.-M., & Devine, W. P. (2022) · Surgical pathology clinics · doi:10.1016/j.path.2022.02.003 · Cited by 3
Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
Abdallah, R. M., Atallah, D. M., Bitar, N., Chahine, G., Ghanem, H., Ghosn, M. G., Kattan, J. G., Nasr, F. L., Makdessi, J., & Shamseddine, A. I. (2023) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2023.101186 · Cited by 3
Successful Treatment of Concurrent Follicular Lymphoma and Triple-Negative Breast Cancer Using Rituximab Plus Nab-Paclitaxel and Cisplatin: A Case Report and Literature Review
Zhu, Z., Zhou, N., Yu, S., Gao, X. Q., Cheng, X., Wang, Y., & Bai, C. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s430273 · Cited by 3
Assessing the Phenotype of a Homologous Recombination Deficiency Using High Resolution Array-Based Comparative Genome Hybridization in Ovarian Cancer
Magadeeva, S., Qian, X., Korff, N., Flörkemeier, I., Hedemann, N., Rogmans, C., Förster, M., Arnold, N., Maass, N., Bauerschlag, D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417467 · Cited by 3
The genomic landscape of breast and non-breast cancers from individuals with germline CHEK2 deficiency
Hinić, S., van der Post, R. S., Vreede, L., Schuurs-Hoeijmakers, J. H. M., Koene, S., Jansen, E. A. M., Bervoets-Metge, F., Mensenkamp, A. R., Hoogerbrugge, N., Ligtenberg, M. J. L., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae044 · Cited by 3
The c.*229C > T gene polymorphism in 3′UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma
Starska, K., Forma, E., Nowacka‐Zawisza, M., Lewy‐Trenda, I., Ciesielski, P., Pietruszewska, W., Skóra, M., & Bryś, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4276-3 · Cited by 3
Loss of Heterozygosity
Gorringe, K. L. (2016) · Wiley eBooks · doi:10.1002/9780470015902.a0026643 · Cited by 3
Genetic Screening of Cervical Cancer
Comparetto, C., & Borruto, F. (2021) · OBM Genetics · doi:10.21926/obm.genet.2103132 · Cited by 3
Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
Chiang, Y., Huang, H., Kuo, K.-T., Hwu, W., Cheng, W., & Lin, P. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-024-01565-3 · Cited by 2
Characterization of Immune Landscape Based on Homologous Recombination Deficiency Associated Signatures and Identification of Knockdown of ERCC6L to Promote Radiosensitivity in Breast Cancer
Li, J., Chen, G., Zhou, H., Liu, J., Ha, W., Jiang, Y., & Xiong, H. (2025) · The Journal of Gene Medicine · doi:10.1002/jgm.70012 · Cited by 2
Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data
Zhu, R., Eason, K., Chin, S., Edwards, P. A., García, R. M., Moulange, R., Pan, J. W., Teo, S., Mukherjee, S., Callari, M., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70041 · Cited by 3
Clinical Trials Investigating PARP Inhibitors as Single Agents
Irshad, S., & Tutt, A. N. J. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_21 · Cited by 2
Self-citation
Triple-Negative Breast Cancer
Vankina, R., & Yuan, Y. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_13 · Cited by 2
The Landscape of Personalized Medicine in Gynecologic Cancer
Foxall, M. E., & Arend, R. C. (2022) · Advances in Oncology · doi:10.1016/j.yao.2022.02.001 · Cited by 2
Breast Cancer and Next-Generation Sequencing: Towards Clinical Relevance and Future
Pereira, M. A., Marinho, F. L. D. O., Leite, L. R., Alvim, L. B., Malta, F. S. V., Marques, F. K., & de Lima, A. B. (2022) · Springer eBooks · doi:10.1007/978-981-19-0197-3_20 · Cited by 3
Enhancing the detection of clinically relevant biomarkers in advanced uterine and tubo-ovarian carcinomas through genome-wide analysis
Assaad, M. A., Hadi, K., Tu, J. J., Levine, M. F., Patel, M. A., Deshpande, A. S., Manohar, J., Sigouros, M., Sboner, A., Chapman‐Davis, E., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155773 · Cited by 2
Potential Therapeutic Targets in Triple Negative Breast Cancer
Azim, H. A., & Azim, H. A. (2015) · Current Breast Cancer Reports · doi:10.1007/s12609-015-0192-1 · Cited by 2
Novel Therapies for Advanced Cervical Cancer
Tewari, K. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803741-6.00014-8 · Cited by 2
Machine learning-based prediction of response to PARP inhibition across cancer typesPreprint
Hill, K. E., Rattani, A., Lietz, C. E., Garbutt, C. C., Choy, E., Cote, G. M., Culhane, A. C., Kelly, A. D., Haibe‐Kains, B., & Spentzos, D. (2019) · medRxiv · doi:10.1101/19007757 · Cited by 2
Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Tan, T. J., Fink, J. L., Tay, T. K. Y., Jaradi, B., Stone, N., Waring, P. M., Koo, K. M., Tan, P. H., Tan, D. S. W., & Dent, R. A. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00309 · Cited by 1
Development of Homologous Recombination Functional Assays for Targeting the DDR
Oswald, A. J., & Gourley, C. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_4 · Cited by 2
HRD Score: A Promising Biomarker for Genomic Instability Evaluation for Targeted Treatments Among Pancreatic Cancer Patients
Wang, X., Zhang, Q., Xu, Y., Miao, W., Tao, B., Jin, C., & Fu, D. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261469099 · Cited by 1
From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors
Ayoub, M. M., Osman, S. A., Alkarbi, R. M., Anjum, R., & Malki, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1894818 · Cited by 1
Emerging Prognostic and Predictive Biomarkers for Triple Negative Breast Cancer
Nag, S. M., Mane, A. D., & Gupta, S. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0165-9 · Cited by 1
Genomic Markers in ER-Negative Breast Cancer
Karn, T., & Hatzis, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-41761-5_19 · Cited by 1
Personalisierte Medizin bei soliden Tumoren
Kast, K., & Arnold, N. (2016) · Medizinische Genetik · doi:10.1007/s11825-016-0116-0 · Cited by 1
A hereditary ovarian cancer family with rare pathogenic splicing mutation: Implications for variant interpretation
Wang, K., Ye, Y., Bao, L., Cheng, Y., Cao, Y., & Yu, J. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.05.007 · Cited by 1
Homologous recombination in mammalian cells: From molecular mechanisms to pathology
Ragu, S., Matos-Rodrigues, G. E., THOMAS, M. L., & López, B. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85679-9.00020-9 · Cited by 2
Avances en el tratamiento de cáncer de ovario, cérvix y endometrio
Pierre, M. E., Hernández, A., Viveros-Carreño, D. A., Cruz, C. C., Bravo, M. A., & Vargas, C. A. (2024) · Medicina · doi:10.56050/01205498.2373 · Cited by 1
Electrochemical aptamer-based biosensors for diagnosis of cancers
Nematollahi, H., Afjeh‐Dana, E., Ghani, S., & Nazari-Vanani, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13633-7.00003-x · Cited by 1
Targeting the DNA Damage Response for Radiosensitization
McMillan, M. T., Lawrence, T. S., & Morgan, M. A. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_9 · Cited by 1
Ovarian cancer—ASCO annual meeting update 2021
Schöche, J., & Strasser‐Weippl, K. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00772-8 · Cited by 1
Faculty Opinions recommendation of Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Lees‐Miller, S. P. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732976037.793546302 · Cited by 1
Reply to: Comments on “Effect of HIPEC according to HRD /BRCA wt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial”
Koole, S. N., Schouten, P. C., van Driel, W. J., Sonke, G. S., & Linn, S. C. (2022) · International Journal of Cancer · doi:10.1002/ijc.34219 · Cited by 1
Overcoming tumor hypoxia
van der Wiel, A. M.-M. A. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230202aw · Cited by 1
Developing a whole exome sequencing-based homologous recombination deficiency test of epithelial ovarian cancerPreprint
Lin, P., Kuo, K.-T., Hwu, W., Huang, H., Lin, T., Chen, C.-M., Cheng, W., & Chiang, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2983608/v1 · Cited by 1
Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity
Hayman, T. J. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae045 · Cited by 1
Diversity in Pathology and Genomics in Ovarian Cancer
Matsumura, N. (2017) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-10-2489-4_7
Cyclin E1 as a therapeutic target in high grade serous ovarian cancer
Au‐Yeung, G. (2017) · Minerva Access (University of Melbourne)
Towards the development of HAGE-based vaccines for the treatment of patients with triple negative breast cancers
Nagarajan, D. (2018) · Nottingham Trent University's Institutional Repository (Nottingham Trent Repository)
Pathogenese und genetischer Hintergrund des Osteosarkoms: Aktuelle Konzepte und Entwicklungen
Baumhoer, D. (2018) · Der Pathologe
Investigation of Intra-tumour Heterogeneity and Host Immune Response in Triple-negative Breast Cancer
Balde, Z. (2020) · TSpace (University of Toronto)
Metastatic Triple Negative Breast Cancer: The New Era of Thinking
Mohammed, A. A., Elbassuiony, M. A., & Rashied, H. (2021) · Forum of Clinical Oncology · doi:10.2478/fco-2018-0007
Critical evaluation of CNA estimators for DNA data using matching confidence masks and WGS technology
Muñoz‐Minjares, J., Shmaliy, Y. S., & Popova, T. G. (2021) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2021.103004
Specific BRCA and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomasPreprint
Menghi, F., Banda, K., Kumar, P., Straub, R., Dobrolecki, L. E., Rodriguez, I. V., Yost, S. E., Chandok, H., Radke, M. R., Zhu, A. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.19.456799
Faculty Opinions recommendation of HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Semple, C. A. M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727392893.793552753
Faculty Opinions recommendation of HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Wyman, C. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727392893.793550423
Faculty Opinions recommendation of An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Plaxe, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732115299.793560788
Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutationsPreprint
Kim, J., Jeong, K., Jun, H., Kim, K., Yi, H., Park, S., Woo, G.-U., Lee, D., Kim, T.-Y., Lee, K.-H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1942928/v1
Data from Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2023) · doi:10.1158/1078-0432.c.6526236
Data from Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2023) · doi:10.1158/1078-0432.c.6526236.v1
Circulating Tumour Cell Isolation and Molecular Profiling; Potential Therapeutic Intervention
Radfar, P., Es, H. A., Kulasinghe, A., Thiery, J. P., & Warkiani, M. E. (2023) · Current cancer research · doi:10.1007/978-3-031-22903-9_14
Genomic instability as a predictive biomarker for the application of DNA-damaging therapies in gynecological cancer patients
Reig, R. L. (2023) · doi:10.4995/thesis/10251/199026
Research Progress of PARP Inhibitors in Maintenance Therapy of Ovarian Cancer
陈, 建. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153649
The Landscape of Personalized Medicine in Gynecologic Cancer
Foxall, M. E., & Arend, R. C. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.04.012
Additional file 3 of Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
Ballot, E., Galland, L., Mananet, H., Boidot, R., Arnould, L., Desmoulins, I., Mayeur, D., Kaderbhaï, C., Ilie, S. M., Hennequin, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21602070
Additional file 5 of Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
Ballot, E., Galland, L., Mananet, H., Boidot, R., Arnould, L., Desmoulins, I., Mayeur, D., Kaderbhaï, C., Ilie, S. M., Hennequin, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21602076
Additional file 4 of Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
Ballot, E., Galland, L., Mananet, H., Boidot, R., Arnould, L., Desmoulins, I., Mayeur, D., Kaderbhaï, C., Ilie, S. M., Hennequin, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21602073

Authors: Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N.
Affiliations: Guy's Hospital (GB)
Corresponding author: Grigoriadis, Anita
ORCID: Watkins, Johnathan A
Irshad, Sheeba
Grigoriadis, Anita
Tutt, Andrew NJ
Venue: Breast Cancer Research
Publisher: Springer Science and Business Media LLC
Published: 2014-06-03
Volume: 16
Issue: 3
Pages: 211-211
ISSN: 1465-5411 (ISSN-L)
1465-542X
DOI: 10.1186/bcr3670
PMC: PMC4053155
OpenAlex: W2100419317
Cited by: 327
References: 58
Citations by year: 2026: 14 · 2025: 14 · 2024: 21 · 2023: 31 · 2022: 54 · 2021: 42 · 2020: 25 · 2019: 25 · 2018: 23 · 2017: 27 · 2016: 35 · 2015: 15 · 2014: 1
FWCI: 2.95
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
www.springer.com/tdm (unspecified)
Locations: Breast Cancer Research (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Research Portal (King's College London) (publishedVersion, other-oa)
Funders: National Institute for Health and Care Research
King's College London
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: homologous recombination deficiency, PARP inhibitors, BRCA1, BRCA2, loss of heterozygosity, telomeric allelic imbalance, mutational signatures, drug response biomarkers, breast cancer, ovarian cancer, DNA double-strand break repair, platinum-based chemotherapy, companion diagnostics, predictive biomarkers
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Breast Neoplasms, Chromosome Aberrations, Female, Humans, Ovarian Neoplasms, Biomarkers, Tumor, BRCA1 Protein, BRCA2 Protein, DNA Breaks, Double-Stranded, Homologous Recombination, Recombinational DNA Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks